Biomarker Panel for COPD Susceptibility Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable and effective ways to predict susceptibility to chronic obstructive pulmonary disease (COPD) and assess its severity in individuals, particularly in identifying those at risk of developing COPD and monitoring disease progression.
Innovation Solution
A method involving the detection and assessment of specific biomarkers such as LMBL3, CAMP, VCAM1, IL1RAP, HGFL, GRP78, and others in biological fluid samples to determine susceptibility and severity of COPD, using a panel of proteins that differ significantly between at-risk subjects and those with severe COPD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to assess COPD susceptibility and severity, then the assessment process is simple, but the reliability and accuracy of prediction are insufficient
Solution Approach 1:
The patent segments the COPD assessment into multiple independent biomarker components (e.g., GRP78, Haptoglobin, Albumin, CRP) that can be measured separately and then integrated. This segmentation allows for systematic evaluation of different physiological aspects (oxidative stress, inflammation, protein synthesis) contributing to COPD susceptibility, thereby improving reliability while maintaining manageable complexity through modular assessment.
Solution Approach 2:
The patent utilizes changes in biomarker parameters (concentrations, ratios, and expression levels) to assess COPD susceptibility. By monitoring parameter changes in specific proteins (e.g., increased GRP78, decreased Haptoglobin) in response to cigarette smoke exposure, the method transforms qualitative susceptibility assessment into quantitative parameter-based evaluation, enhancing reliability without excessive complexity.
2Measurement precision
If a panel of multiple biomarkers is used to assess COPD susceptibility, then the measurement precision improves, but the device complexity and cost increase
Solution Approach 1:
The patent employs a multi-functional biomarker panel where each biomarker serves multiple assessment purposes. For example, GRP78 levels indicate both oxidative stress response and unfolded protein response activation, while Haptoglobin levels reflect both inflammation and oxidative damage. This universality allows a single biomarker to contribute to multiple aspects of COPD assessment, improving measurement precision without proportionally increasing system complexity.
Solution Approach 2:
The patent utilizes parameter changes in biomarker concentrations, ratios, and expression patterns to achieve precise COPD assessment. By measuring parameter changes (e.g., GRP78/Haptoglobin ratio, Albumin/CRP ratio) rather than single absolute values, the method enhances measurement precision through comparative analysis, allowing for more accurate risk stratification while using standard laboratory techniques.
Data Source
AI summary
The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.